Literature DB >> 28502718

Mitochondrial ND5 mutation mediated elevated ROS regulates apoptotic pathway epigenetically in a P53 dependent manner for generating pro-cancerous phenotypes.

Rajnish Kumar Singh1, Sunil Saini1, Dileep Verma1, Ponnusamy Kalaiarasan1, Rameshwar N K Bamezai2.   

Abstract

We have previously observed concomitant events of mutations in mitochondrial and nuclear genes, along with elevated reactive oxygen species (ROS) and differential methylation within the promoters of nuclear genes in tumors and in vitro experiments of tumorigenesis. These observations have made it pertinent to replicate and understand the role of acquired mitochondrial condition in tuning a cell to accomplish a pro-cancerous state. Using a codon optimized vector system for exogenous over-expression and mitochondrial localization; we have characterized here the role of over-expressed wild type mtND5 and one of its non-synonymous somatic mutation, ND5:P265H. The ectopically over-expressed ND5:P265H in mitochondria resulted in a reduced Complex I activity, generation of higher ADP/ATP ratio, reactive oxygen species (ROS) and carbonylation of proteins as compared to mock-transfected cells. Cells over-expressing mtND5 variant produced both peroxide as well as super-oxide ROS; the generation of which was dependent on the functional status of P53; modulating epigenetically the expression of key apoptosis pathway genes. The pro-cancerous phenotypes, of anchorage dependent and independent growth; increased glucose uptake and lactate production, were selectively observed only in P53 non-functional cells over-expressing mutant ND5:P265H. We propose that somatic mutation in mtND5 resulting in down-regulated complex I enzyme activity, elevated ROS and up-regulation of a set of nuclear anti-apoptotic genes epigenetically in the P53 dysfunctional cellular background, has provided a unique understanding of the molecular mechanism of mitochondrial mutation; and the concomitant existence of somatically acquired mitochondrial and nuclear p53 mutations, in cancer progression and promotion.
Copyright © 2017. Published by Elsevier B.V.

Entities:  

Keywords:  Apoptotic pathway; Differential methylation; Mitochondrial DNA mutation; Reactive oxygen species; mtND5

Mesh:

Substances:

Year:  2017        PMID: 28502718     DOI: 10.1016/j.mito.2017.05.001

Source DB:  PubMed          Journal:  Mitochondrion        ISSN: 1567-7249            Impact factor:   4.160


  6 in total

1.  Dissecting the expression landscape of mitochondrial genes in lung squamous cell carcinoma and lung adenocarcinoma.

Authors:  Nan Li; Jing Zhao; Yibing Ma; Bhaskar Roy; Ren Liu; Karsten Kristiansen; Qiang Gao
Journal:  Oncol Lett       Date:  2018-07-10       Impact factor: 2.967

2.  Landscape of Germline and Somatic Mitochondrial DNA Mutations in Pediatric Malignancies.

Authors:  Petr Triska; Kristiyana Kaneva; Daria Merkurjev; Noor Sohail; Marni J Falk; Timothy J Triche; Jaclyn A Biegel; Xiaowu Gai
Journal:  Cancer Res       Date:  2019-02-01       Impact factor: 12.701

3.  Mitochondrial Cardiomyopathy Caused by Elevated Reactive Oxygen Species and Impaired Cardiomyocyte Proliferation.

Authors:  Donghui Zhang; Yifei Li; Danielle Heims-Waldron; Vassilios Bezzerides; Silvia Guatimosim; Yuxuan Guo; Fei Gu; Pingzhu Zhou; Zhiqiang Lin; Qing Ma; Jianming Liu; Da-Zhi Wang; William T Pu
Journal:  Circ Res       Date:  2017-10-11       Impact factor: 17.367

Review 4.  Multifaceted Roles of Mitochondrial Components and Metabolites in Metabolic Diseases and Cancer.

Authors:  Jean Nakhle; Anne-Marie Rodriguez; Marie-Luce Vignais
Journal:  Int J Mol Sci       Date:  2020-06-20       Impact factor: 5.923

5.  Mitochondria in tumour progression: a network of mtDNA variants in different types of cancer.

Authors:  Giovanna C Cavalcante; Ândrea Ribeiro-Dos-Santos; Gilderlanio S de Araújo
Journal:  BMC Genom Data       Date:  2022-02-18

6.  Pathogenic Heteroplasmic Somatic Mitochondrial DNA Mutation Confers Platinum-Resistance and Recurrence of High-Grade Serous Ovarian Cancer.

Authors:  Jing Ni; Yan Wang; Xianzhong Cheng; Fang Teng; Congyang Wang; Suping Han; Xiaoxiang Chen; Wenwen Guo
Journal:  Cancer Manag Res       Date:  2020-11-02       Impact factor: 3.989

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.